Last reviewed · How we verify
JMKX003142 will be administered orally
At a glance
| Generic name | JMKX003142 will be administered orally |
|---|---|
| Also known as | JMKX003142 |
| Sponsor | Jemincare |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PHASE2)
- Phase 1 Clinical Study of JMKX003142 Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JMKX003142 will be administered orally CI brief — competitive landscape report
- JMKX003142 will be administered orally updates RSS · CI watch RSS
- Jemincare portfolio CI